Dr. Sola Pioneered New Protocol Using Masimo
SET® Pulse Oximetry That Dramatically Reduced Blindness and Eye
Damage in Neonates
Masimo (NASDAQ: MASI) announced today that Augusto Sola, MD,
Vice President of Medical Affairs for Neonatology at Masimo, has
been awarded the 2020 Pioneer Award, Section of Neonatal Perinatal
Medicine, by the American Academy of Pediatrics (AAP). The honor
recognizes the groundbreaking achievements and contributions Dr.
Sola has made, using his Masimo SET®-based protocol, to improve the
health and well-being of newborn infants.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201019005215/en/
Dr. Augusto Sola (Photo: Business
Wire)
Dr. Sola’s impressive career in neonatology has improved the
lives of countless newborns in the U.S., Latin America, and across
the world. Dr. Sola’s innovative research on oxygen administration
and monitoring oxygen saturation in preterm infants has played a
key role in reducing the rate of neonatal blindness (retinopathy of
prematurity) and our understanding of the impact of various
neonatal practices on the developing brain. Dr. Sola has published
130 original articles in peer-reviewed journals, 390 review
articles, and 5 neonatology textbooks, as well as delivered more
than 3,500 lectures to research and clinical groups around the
world. Dr. Sola also founded the Ibero-American Society of
Neonatology (SIBEN), dedicated to continuous quality improvement in
neonatal care throughout the Americas.
Dr. Sola received his MD at Buenos Aires University School of
Medicine and completed his Pediatric Residency and Chief Pediatric
Residency at the University of Massachusetts, followed by a
Neonatal Fellowship at the University of California, San Francisco.
In neonatal practice since 1974, Dr. Sola has been Professor of
Pediatrics at Buenos Aires University Medical School, the
University of California, San Francisco, the University of
California, Los Angeles, and Emory University. In addition to his
position at Masimo, Dr. Sola continues to work directly with
critically ill newborns.
Dr. Sola’s seminal work was done in 1998 at Cedars-Sinai Medical
Center in Los Angeles. The results, published in 2003 by Drs. Sola,
Wright, and Chow, showed that using a new protocol with Masimo
SET®, clinicians reduced ROP to nearly zero over five years.1 Dr.
Sola and colleagues later showed at Emory that the protocol’s
success depended on SET® technology, as the same protocol with a
competing pulse oximeter did not reduce ROP.2 Dr. Sola’s work on
the reduction of ROP through oxygen saturation targeting has now
become the standard of care.3-5
Dr. Sergio Golombek, MD, MPH, Professor of Pediatrics at New
York Medical College, Neonatologist, Ex-President of SIBEN, and AAP
member, commented, “In 1952, a Chicago newspaper wrote: ‘The best
friend a baby ever had,’ referring to pediatrician Isaac A. Abt,
MD, FAAP (1867-1955), founder of the AAP and its first president in
1930. He was known as a leading clinician, academic, advocate,
promoter, writer, and leader. I think this has been overcome by Dr.
Sola, who is, in my opinion, the best friend of a baby and his or
her parents and of the many neonatal professionals and trainees
whom he trained!”
Joe Kiani, Founder and CEO of Masimo, said, “We are incredibly
proud of Dr. Sola, a brilliant and caring doctor whom I have had
the privilege of knowing for many years. Dr. Sola’s pioneering work
on the oxygen saturation of neonates has made a significant impact
on the prevention of blindness in infants, and his contributions to
our understanding of neonatal physiology are vast. It is only
fitting that the American Academy of Pediatrics has chosen to honor
him. We are grateful to benefit from his expertise at Masimo, which
has been especially dedicated, ever since its founding, to
improving outcomes for the youngest and most fragile patients.
Congratulations, Dr. Sola, on this well-deserved recognition.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.6 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,7 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.8-11 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,12 and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S.
News and World Report Best Hospitals Honor Roll.13 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris Gateway®,
Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and
Masimo SafetyNet™. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Chow LC, Wright KW, Sola A. Can Changes in Clinical Practice
Decrease the Incidence of Severe Retinopathy of Prematurity in Very
Low Birth Weight Infants? Pediatrics. 2003 Feb;111(2):339-45.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- Bizzarro MJ et al. Temporal Quantification of Oxygen Saturation
Ranges: An Effort to Reduce Hyperoxia in the Neonatal Intensive
Care Unit. J Perinatol. 2014 Jan;34(1):33-8
- Baquero H et al. Avoiding Hyperoxemia during Neonatal
Resuscitation: Time to Response of Different SpO2 Monitors. Acta
Paediatr. 2011 Apr;100(4):515-8.
- Sola A et al. Safe oxygen saturation targeting and monitoring
in preterm infants: can we avoid hypoxia and hyperoxia? Acta
Paediatr. 2014 Oct;103(10):1009-18. doi: 10.1111/apa.12692.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SET®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SET®, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005215/en/
Media Contact: Masimo Evan Lamb 949-396-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024